Traders Union
All News
Gene therapy, rare neurological diseases, and biotech research by Neurogene

Advertiser Disclosure

Gene therapy, rare neurological diseases, and biotech research by Neurogene

Neurogene Inc. finalizes administration phase in pivotal Embolden study

Dmytro Kharkov
08.06.2026

Neurogene Inc. finalizes administration phase in pivotal Embolden study

Neurogene Inc. announced the successful completion of dosing in its Embolden registrational clinical trial. This marks a key milestone for the experimental therapy, as the company advances its ...

Neurogene Inc. unveils new data on ICV gene therapy approach at ASGCT2026

Hanna Syniavska
12.05.2026

Neurogene Inc. unveils new data on ICV gene therapy approach at ASGCT2026

Neurogene Inc. is presenting new findings supporting the therapeutic rationale for intracerebroventricular (ICV) delivery in CNS-targeted gene therapy at the ASGCT2026 conference. The ...

ICV delivery approach for CNS gene therapy set for American Society of Gene and Cell Therapy meeting, Neurogene Inc.

Parshwa Turakhiya
28.04.2026

ICV delivery approach for CNS gene therapy set for American Society of Gene and Cell Therapy meeting, Neurogene Inc.

Neurogene Inc. has announced plans to present new research on the rationale for intracerebroventricular (ICV) delivery in central nervous system (CNS)-targeted gene therapy at the upcoming ...

Neurogene Inc. appoints Christy Shafer as Chief Commercial Officer and adds Christine Mikail to board

Igor Krasulya
20.04.2026

Neurogene Inc. appoints Christy Shafer as Chief Commercial Officer and adds Christine Mikail to board

Neurogene Inc. announced two key leadership moves, naming Christy Shafer as Chief Commercial Officer and appointing Christine Mikail to its Board of Directors in addition to her existing roles as ...

NGN-401 clinical developments and financials drive Neurogene Inc. corporate update

Dmytro Kharkov
24.03.2026

NGN-401 clinical developments and financials drive Neurogene Inc. corporate update

Neurogene Inc. released its full year 2025 financial results today, providing investors with insights into the company’s performance and strategic direction. Alongside the financial ...

Neurogene Inc. wins FDA Breakthrough Therapy Designation for NGN-401 gene therapy

Artem Shendetskii
27.02.2026

Neurogene Inc. wins FDA Breakthrough Therapy Designation for NGN-401 gene therapy

The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to NGN-401, the potential best-in-class gene therapy developed by Neurogene Inc. for Rett syndrome. This ...

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.